Literature DB >> 14672739

Oxidative 3alpha-hydroxysteroid dehydrogenase activity of human type 10 17beta-hydroxysteroid dehydrogenase.

Xue-Ying He1, Ying-Zi Yang, Donna M Peehl, Alexander Lauderdale, Horst Schulz, Song-Yu Yang.   

Abstract

In vitro enzyme assays have demonstrated that human type 10 17beta-hydroxysteroid dehydrogenase (17beta-HSD10) catalyzes the oxidation of 5alpha-androstane-3alpha,17beta-diol (adiol), an almost inactive androgen, to dihydrotestosterone (DHT) rather than androsterone or androstanedione. To further investigate the role of this steroid-metabolizing enzyme in intact cells, we produced stable transfectants expressing 17beta-HSD10 or its catalytically inactive Y168F mutant in human embryonic kidney (HEK) 293 cells. It was found that DHT levels in HEK 293 cells expressing 17beta-HSD10, but not its catalytically inactive mutant, will dramatically increase if adiol is added to culture media. Moreover, certain malignant prostatic epithelial cells have more 17beta-HSD10 than normal controls, and can generate DHT, the most potent androgen, from adiol. This event might promote prostate cancer growth. Analysis of the 17beta-HSD10 sequence shows that this enzyme does not have any ER retention signal or transmembrane segments and has not originated by divergence from a retinol dehydrogenase. The data suggest that the unique mitochondrial location of this HSD [Eur. J. Biochem. 268 (2001) 4899] does not prevent it from oxidizing the 3alpha-hydroxyl group of a C19 sterol in living cells. The experimental results lead to the conclusion that mitochondrial 17beta-HSD10 plays a significant part in a non-classical androgen synthesis pathway along with microsomal retinol dehydrogenases.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14672739     DOI: 10.1016/j.jsbmb.2003.07.007

Source DB:  PubMed          Journal:  J Steroid Biochem Mol Biol        ISSN: 0960-0760            Impact factor:   4.292


  12 in total

1.  Determination of small molecule ABAD inhibitors crossing blood-brain barrier and pharmacokinetics.

Authors:  Jhansi Rani Vangavaragu; Koteswara Rao Valasani; Du Fang; Todd D Williams; Shirley ShiDu Yan
Journal:  J Alzheimers Dis       Date:  2014       Impact factor: 4.472

2.  Potential prostate cancer drug target: bioactivation of androstanediol by conversion to dihydrotestosterone.

Authors:  James L Mohler; Mark A Titus; Elizabeth M Wilson
Journal:  Clin Cancer Res       Date:  2011-06-24       Impact factor: 12.531

Review 3.  Neurosteroidogenesis Today: Novel Targets for Neuroactive Steroid Synthesis and Action and Their Relevance for Translational Research.

Authors:  P Porcu; A M Barron; C A Frye; A A Walf; S-Y Yang; X-Y He; A L Morrow; G C Panzica; R C Melcangi
Journal:  J Neuroendocrinol       Date:  2016-02       Impact factor: 3.627

4.  Activation of the androgen receptor by intratumoral bioconversion of androstanediol to dihydrotestosterone in prostate cancer.

Authors:  James L Mohler; Mark A Titus; Suxia Bai; Brian J Kennerley; Fred B Lih; Kenneth B Tomer; Elizabeth M Wilson
Journal:  Cancer Res       Date:  2011-02-08       Impact factor: 12.701

5.  Quantitative proteomic profiling of prostate cancer reveals a role for miR-128 in prostate cancer.

Authors:  Amjad P Khan; Laila M Poisson; Vadiraja B Bhat; Damian Fermin; Rong Zhao; Shanker Kalyana-Sundaram; George Michailidis; Alexey I Nesvizhskii; Gilbert S Omenn; Arul M Chinnaiyan; Arun Sreekumar
Journal:  Mol Cell Proteomics       Date:  2009-11-09       Impact factor: 5.911

Review 6.  Classical and Non-Classical Roles for Pre-Receptor Control of DHT Metabolism in Prostate Cancer Progression.

Authors:  Ailin Zhang; Jiawei Zhang; Stephen Plymate; Elahe A Mostaghel
Journal:  Horm Cancer       Date:  2016-01-21       Impact factor: 3.869

7.  Dominant-negative androgen receptor inhibition of intracrine androgen-dependent growth of castration-recurrent prostate cancer.

Authors:  Mark A Titus; Brian Zeithaml; Boris Kantor; Xiangping Li; Karin Haack; Dominic T Moore; Elizabeth M Wilson; James L Mohler; Tal Kafri
Journal:  PLoS One       Date:  2012-01-17       Impact factor: 3.240

8.  Comparative evolutionary genomics of the HADH2 gene encoding Abeta-binding alcohol dehydrogenase/17beta-hydroxysteroid dehydrogenase type 10 (ABAD/HSD10).

Authors:  Alexandra T Marques; Agostinho Antunes; Pedro A Fernandes; Maria J Ramos
Journal:  BMC Genomics       Date:  2006-08-09       Impact factor: 3.969

9.  Studies on the analysis of 25-hydroxyvitamin D(3) by isotope-dilution liquid chromatography-tandem mass spectrometry using enzyme-assisted derivatisation.

Authors:  Jonas Abdel-Khalik; Peter J Crick; Graham D Carter; Hugh L Makin; Yuqin Wang; William J Griffiths
Journal:  Biochem Biophys Res Commun       Date:  2014-01-30       Impact factor: 3.575

10.  Steroid hormone synthetic pathways in prostate cancer.

Authors:  Elahe A Mostaghel
Journal:  Transl Androl Urol       Date:  2013-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.